Cantargia: Early Haematology Signal Ahead of ASH Oral - Redeye

Cantargia: Early Haematology Signal Ahead of ASH Oral - Redeye

Cantargia has published an ASH abstract from the investigator-initiated phase Ib/IIa trial of nadunolimab in higher-risk MDS and R/R AML. The data will be presented orally on 13 December. The results are early but encouraging.

Länk till analysen i sin helhet: https://www.redeye.se/research/1190946/cantargia-early-haematology-signal-ahead-of-ash-oral?utm_source=finwire&utm_medium=RSS